Aneta Suder

Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

Linda Mileshkin, Kathleen N. Moore, Elizabeth H Barnes et al. · The Lancet Oncology · 2023 · 190 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

Arun Azad, Mathias Bressel, Hsiang Tan et al. · The Lancet Oncology · 2024 · 111 citations

Medicine, Oncology, Urology +12

Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials

Aisyah Mohd Noor, Debashis Sarker, Suzanne Vizor et al. · Journal of Clinical Oncology · 2012 · 59 citations · Full text

Medicine, Oncology, Cancer Epidemiology +14

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours

Aneta Suder, J.E. Ang, Fiona Kyle et al. · European Journal of Cancer · 2015 · 28 citations · Full text

Medicine, Oncology, Pharmacology +11

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours

James Spicer, Richard D. Baird, Aneta Suder et al. · European Journal of Cancer · 2014 · 15 citations · Full text

Medicine, Oncology, Pharmacology +13